Literature DB >> 33552954

Comprehensive Characterization of Immunological Profiles and Clinical Significance in Hepatocellular Carcinoma.

Ping Tao1, Liang Hong2, Wenqing Tang3, Qun Lu1, Yanrong Zhao1, Si Zhang4, Lijie Ma2,5, Ruyi Xue3.   

Abstract

BACKGROUND: Therapies targeting immune molecules have rapidly been adopted and advanced the treatment of hepatocellular carcinoma (HCC). Nonetheless, no studies have reported a systematic analysis between immunological profiles and clinical significance in HCC.
METHODS: We comprehensively investigated immune patterns and systematically correlated 22 types of both adaptive and innate immune cells with genomic characteristics and clinical outcomes based on 370 HCC patients from The Cancer Genome Atlas (TCGA) database through a metagene approach (known as CIBERSORT). Based on the Quantitative Pathology Imaging and Analysis System coupled with integrated high-dimensional bioinformatics analysis, we further independently validated six immune subsets (CD4+ T cells, CD8+ T cells, CD20+ B cells, CD14+ monocytes, CD56+ NK cells, and CD68+ macrophages), and shortlisted three (CD4+ T cells, CD8+ T cells, and CD56+ NK cells) of which to investigate their association with clinical outcomes in two independent Zhongshan cohorts of HCC patients (n = 258 and n = 178). Patient prognosis was further evaluated by Kaplan-Meier analysis and univariate and multivariate regression analysis.
RESULTS: By using the CIBERSORT method, the immunome landscape of HCC was constructed based on integrated transcriptomics analysis and multiplexed sequential immunohistochemistry. Further, the patients were categorized into four immune subgroups featured with distinct clinical outcomes. Strikingly, significant inter-tumoral and intra-tumoral immune heterogeneity was further identified according to the in-depth interrogation of the immune landscape.
CONCLUSION: This work represents a potential useful resource for the immunoscore establishment for prognostic prediction in HCC patients.
Copyright © 2021 Tao, Hong, Tang, Lu, Zhao, Zhang, Ma and Xue.

Entities:  

Keywords:  hepatocellular carcinoma; heterogeneity; landscape; prognosis; tumor microenvironment

Year:  2021        PMID: 33552954      PMCID: PMC7862794          DOI: 10.3389/fonc.2020.574778

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  52 in total

Review 1.  Molecular therapies and precision medicine for hepatocellular carcinoma.

Authors:  Josep M Llovet; Robert Montal; Daniela Sia; Richard S Finn
Journal:  Nat Rev Clin Oncol       Date:  2018-10       Impact factor: 66.675

2.  PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression.

Authors:  Xiao Xiao; Xiang-Ming Lao; Min-Min Chen; Rui-Xian Liu; Yuan Wei; Fang-Zhu Ouyang; Dong-Ping Chen; Xiao-Yu Zhao; Qiyi Zhao; Xue-Feng Li; Chuan-Lu Liu; Limin Zheng; Dong-Ming Kuang
Journal:  Cancer Discov       Date:  2016-02-29       Impact factor: 39.397

3.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Authors:  Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2018-06-03       Impact factor: 41.316

4.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

5.  Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification.

Authors:  Yutaka Kurebayashi; Hidenori Ojima; Hanako Tsujikawa; Naoto Kubota; Junki Maehara; Yuta Abe; Minoru Kitago; Masahiro Shinoda; Yuko Kitagawa; Michiie Sakamoto
Journal:  Hepatology       Date:  2018-07-25       Impact factor: 17.425

6.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Jordi Bruix; Shukui Qin; Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; György Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; René Gerolami; Gianluca Masi; Paul J Ross; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Ann-Lii Cheng; Josep M Llovet; Richard S Finn; Marie-Aude LeBerre; Annette Baumhauer; Gerold Meinhardt; Guohong Han
Journal:  Lancet       Date:  2016-12-06       Impact factor: 79.321

7.  Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer.

Authors:  Lichun Ma; Maria O Hernandez; Yongmei Zhao; Monika Mehta; Bao Tran; Michael Kelly; Zachary Rae; Jonathan M Hernandez; Jeremy L Davis; Sean P Martin; David E Kleiner; Stephen M Hewitt; Kris Ylaya; Bradford J Wood; Tim F Greten; Xin Wei Wang
Journal:  Cancer Cell       Date:  2019-10-03       Impact factor: 31.743

8.  Profiling Tumor Infiltrating Immune Cells with CIBERSORT.

Authors:  Binbin Chen; Michael S Khodadoust; Chih Long Liu; Aaron M Newman; Ash A Alizadeh
Journal:  Methods Mol Biol       Date:  2018

Review 9.  Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis.

Authors:  Qiaofen Fu; Nan Chen; Chunlei Ge; Ruilei Li; Zhen Li; Baozhen Zeng; Chunyan Li; Ying Wang; Yuanbo Xue; Xin Song; Heng Li; Gaofeng Li
Journal:  Oncoimmunology       Date:  2019-04-03       Impact factor: 8.110

10.  Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer.

Authors:  Y Ino; R Yamazaki-Itoh; K Shimada; M Iwasaki; T Kosuge; Y Kanai; N Hiraoka
Journal:  Br J Cancer       Date:  2013-02-05       Impact factor: 7.640

View more
  2 in total

1.  Differential expression of insulin-like growth factor type 1 receptor identifies heterogeneous intrahepatic regulatory T subsets in mouse hepatocellular carcinoma.

Authors:  Yabing Huang; Ling Huang; Jiling Zhu; Yin Wu; Jinzhi Shi; Kai Dai
Journal:  Clin Exp Immunol       Date:  2022-05-13       Impact factor: 5.732

2.  The Prognostic Value of Natural Killer Cells and Their Receptors/Ligands in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Jun-Shuai Xue; Zi-Niu Ding; Guang-Xiao Meng; Lun-Jie Yan; Hui Liu; Hai-Chao Li; Sheng-Yu Yao; Bao-Wen Tian; Zhao-Ru Dong; Zhi-Qiang Chen; Jian-Guo Hong; Dong-Xu Wang; Tao Li
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.